Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O et al (2023) Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19. Ther Drug Monit 45(2):191–199

Article  CAS  PubMed  Google Scholar 

Fu R, Tajima S, Suetsugu K, Watanabe H, Egashira N, Masuda S (2019) Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. Acta Pharmacol Sin 40(2):151–159

Article  CAS  PubMed  Google Scholar 

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L et al (2019) Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261–307

Article  CAS  PubMed  Google Scholar 

Berar Yanay N, Bogner I, Saker K, Tannous E (2022) Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19. Clin Drug Investig 42(8):693–695

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gregoor PJ, van Gelder T, van der Ende ME, Ijzermans JN, Weimar W (1999) Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation 68(8):1210

Article  CAS  PubMed  Google Scholar 

Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 90(5):666–673

Article  CAS  PubMed  Google Scholar 

Tang Y, Li Y, Song T (2023) Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: a review of immunosuppressant adjustment strategies. Front Immunol 14:1150341

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E (2022) Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for COVID-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie 77(5):509–521

Article  PubMed  PubMed Central  Google Scholar 

Devresse A, Briol S, De Greef J, Lemaitre F, Boland L, Haufroid V et al (2022) Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2. Kidney Int Rep 7(11):2356–63

Article  PubMed  PubMed Central  Google Scholar 

Lange NW, Salerno DM, Jennings DL, Choe J, Hedvat J, Kovac DB et al (2022) Nirmatrelvir/ritonavir use: managing clinically significant drug-drug interactions with transplant immunosuppressants. Am J Transplant 22(7):1925–1926

Article  CAS  PubMed  Google Scholar 

Wang AX, Koff A, Hao D, Tuznik NM, Huang Y (2022) Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant 22(8):2117–2119

Article  CAS  PubMed  Google Scholar 

Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R et al (2022) Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther 112(1):101–111

Article  CAS  PubMed  Google Scholar 

Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O et al (2022) Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment. Clin Pharmacol Ther 112(4):892–900

Article  CAS  PubMed  Google Scholar 

Dong R, Huang Y, Ling X, Li L, Yu W, Jiang S (2023) High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy. Int J Antimicrob Agents 63(1):106997

Article  PubMed  Google Scholar 

Hiremath S, McGuinty M, Argyropoulos C, Brimble KS, Brown PA, Chagla Z et al (2022) Prescribing nirmatrelvir/ritonavir for COVID-19 in advanced CKD. Clin J Am Soc Nephrol 17(8):1247–1250

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kale A, Shelke V, Dagar N, Anders HJ, Gaikwad AB (2023) How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front Pharmacol 14:1053814

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35(4):275–91

Article  CAS  PubMed  Google Scholar 

Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A et al (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 41(5):898–905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E et al (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26(6):552–561

CAS  PubMed  Google Scholar 

Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ et al (2011) CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit 33(4):417–424

Article  CAS  PubMed  PubMed Central  Google Scholar